Factors Influencing Non-albicans Candidemia: A Case–Case–Control Study

[1]  Y. Wiener-Well,et al.  Antibiotic Exposure as a Risk Factor for Fluconazole-Resistant Candida Bloodstream Infection , 2012, Antimicrobial Agents and Chemotherapy.

[2]  F. Chang,et al.  Candida albicans versus non-albicans bloodstream infections: the comparison of risk factors and outcome. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[3]  G. Samonis,et al.  Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans. , 2011, Medical mycology.

[4]  M. Cuenca‐Estrella,et al.  Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  E. Boltshauser,et al.  Differences in risk-factors, aetiology and outcome between children and young adults with acute ischaemic stroke , 2010 .

[6]  J. Cisneros,et al.  Risk Factors for Fluconazole-Resistant Candidemia , 2010, Antimicrobial Agents and Chemotherapy.

[7]  Y. Carmeli,et al.  Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Falagas,et al.  Candida Albicans Versus Non-Albicans Intensive Care Unit-Acquired Bloodstream Infections: Differences in Risk Factors and Outcome , 2008, Anesthesia and analgesia.

[9]  J. Vazquez,et al.  Epidemiology, Risk Factors, and Outcomes of Candida albicans Versus Non-albicans Candidemia in Nonneutropenic Patients , 2007, The Annals of pharmacotherapy.

[10]  M. Falagas,et al.  Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans. , 2006, Medical mycology.

[11]  S. Filler,et al.  Current treatment strategies for disseminated candidiasis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Michael Y. Lin,et al.  Prior Antimicrobial Therapy and Risk for Hospital-Acquired Candida glabrata and Candida krusei Fungemia: a Case-Case-Control Study , 2005, Antimicrobial Agents and Chemotherapy.

[13]  J. Berlin,et al.  The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Y. Carmeli,et al.  The Case-Case-Control Study Design: Addressing the Limitations of Risk Factor Studies for Antimicrobial Resistance , 2005, Infection Control & Hospital Epidemiology.

[15]  M. Ghannoum,et al.  Effect of Parenteral Antibiotic Administration on Establishment of Intestinal Colonization by Candida glabrata in Adult Mice , 2005, Antimicrobial Agents and Chemotherapy.

[16]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Lee H. Harrison,et al.  Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.

[18]  R. Salomão,et al.  High rate of non-albicans candidemia in Brazilian tertiary care hospitals. , 1999, Diagnostic microbiology and infectious disease.

[19]  B. Lebeau,et al.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  L. Nicolle,et al.  Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[21]  R. Salomão,et al.  Risk Factors for Death in Patients With Candidemia , 1998, Infection Control & Hospital Epidemiology.

[22]  M. Ghannoum,et al.  Mechanism of Fluconazole Resistance inCandida krusei , 1998, Antimicrobial Agents and Chemotherapy.

[23]  E. Anaissie,et al.  The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  D. Snydman,et al.  Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. , 1995, Archives of internal medicine.

[25]  A. Gikas,et al.  Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans , 1993, Antimicrobial Agents and Chemotherapy.

[26]  V. Fraser,et al.  Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  V. Avkan-Oğuz,et al.  Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study. , 2011, Medical mycology.

[28]  M. Pfaller,et al.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  W. Hope,et al.  Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. , 2002, The Journal of hospital infection.